# clm_802196BED548

subject: Regeneron Pharmaceuticals (/record/regeneron-pharmaceuticals.md)  
predicate: quarterly_net_income  
value: 817,800,000 United States dollar  
valid_from: 2023-03-31  
valid_to: 2023-06-30  
published: 2023-05-04  
recorded: 2026-11-08  
confidence: 0.95  
status: superseded  
assertable: true  
superseded_by: clm_0598850A1A59  
last_updated: 2026-11-08  
cite: AsOf. "Regeneron Pharmaceuticals quarterly net income: 817,800,000 United States dollar", as of 2023-03-31 (until 2023-06-30). Claim clm_802196BED548, https://asof.is/claim/clm_802196BED548, accessed 2026-11-09. Source: https://www.sec.gov/Archives/edgar/data/872589/000180422023000016/0001804220-23-000016-index.htm.  
checked: 2026-11-08 · parsed from the SEC filing  
parsed from: us-gaap:NetIncomeLoss in 10-Q Q1 FY2023, filed 2023-05-04  

## Sources

- https://www.sec.gov/Archives/edgar/data/872589/000180422023000016/0001804220-23-000016-index.htm (primary, SEC EDGAR 10-Q Q1 FY2023, published 2023-05-04)

## Supersedes

- [Regeneron Pharmaceuticals](/record/regeneron-pharmaceuticals.md) | quarterly_net_income | 1,315,700,000 United States dollar | valid 2022-09-30 to 2023-03-31 | conf 0.95 | superseded | superseded_by [clm_802196BED548](/claim/clm_802196BED548.md) | [clm_165D233486E7](/claim/clm_165D233486E7.md)

---

AsOf is a temporal fact ledger: a structured, dated, sourced record of what is true and what changed, built for AI retrieval.